* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NSISN vs LIN, SHW, ECL: FCF Margin % Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B FCF Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (MEX:NSISN) has a FCF Margin % of 6.61% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novonesis (Novozymes) B and its competitors. This is 61% below median its historical median of 16.77. Over the past decade, Novonesis (Novozymes) B's FCF Margin % has ranged from 6.36 to 24.37. According to the industry distribution chart, Novonesis (Novozymes) B ranks #87 out of 1581 companies in the Chemicals industry, placing it in the top 5.5%.
Is Novonesis (Novozymes) B's FCF Margin % too high?
Novonesis (Novozymes) B's current FCF Margin % of 6.61% is 61% below median its 10-year median of 16.77. Over the past 10 years, this metric has ranged from a low of 6.36 to a high of 24.37. The Chemicals industry median FCF Margin % is 1.78. Novonesis (Novozymes) B's value of 6.61% is 271.3% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #87 out of 1581 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's FCF Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #87 out of 1581 companies for FCF Margin %. This places Novonesis (Novozymes) B in the top 6% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 1.78. Novonesis (Novozymes) B's value of 6.61% is 271.3% above this benchmark. Historically, Novonesis (Novozymes) B's own FCF Margin % has ranged from 6.36 to 24.37 over the past decade. While the company's 10-year median is 16.77 vs. the industry median of 1.78, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Chemicals company?
The median FCF Margin % among Chemicals companies is 1.78, based on 1,581 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current FCF Margin % of 6.61% is 271.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median FCF Margin % is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current FCF Margin % is 6.61%, which is 61% below median its own 10-year median of 16.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current FCF Margin % of 6.61%. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current FCF Margin % is 6.61%, which is 61% below median its 10-year median of 16.77 and 271.3% above the Chemicals industry median of 1.78. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current FCF Margin % is 6.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.
Key valuation signals for MEX:NSISN:
FCF Margin %: 6.61% (61% below median its 10-year median of 16.77)
GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
Industry Position: 271.3% above the Chemicals median (#87 of 1581)
No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score
Get the complete analysis for MEX:NSISN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NSISN has been successfully added to your 
